Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Trial Profile

Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2016

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top